Preimplantation Genetic Testing Market Size, Share, Trends, Growth Outlook

Preimplantation Genetic Testing Market is estimated to increase at a Compounded Annual Growth Rate of 8.8% CAGR over the forecast period from 2024 to 2030

The Preimplantation Genetic Testing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), By Product (Reagents and Consumables, Instruments, Software and Services), By Application (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-Linked Disorders, HLA Typing, Gender Identification), By Cycle (Fresh non-Donor, Frozen non-Donor, Fresh Donor, Frozen Donor), By End-User (Fertility Clinics, Hospitals, Diagnostic Laboratories, Others).

An Introduction to Preimplantation Genetic Testing Market in 2024

Preimplantation Genetic Testing (PGT) is a specialized genetic screening technique used during in vitro fertilization (IVF) to assess the genetic status of embryos before implantation to the uterus. PGT involves the biopsy of embryos to obtain genetic material for analysis, followed by genetic testing for chromosomal abnormalities, single gene disorders, or structural rearrangements. PGT enables the selection of embryos free of genetic abnormalities for transfer, reducing the risk of inherited diseases and improving the success rates of IVF cycles. Different PGT techniques include PGT-A (aneuploidy screening), PGT-M (monogenic disorder screening), and PGT-SR (structural rearrangement screening), tailored to specific genetic testing needs. As assisted reproductive technologies advance, PGT continues to evolve with improvements in testing accuracy, embryo biopsy techniques, and embryo cryopreservation methods, offering hope to couples seeking to build healthy families and overcome genetic infertility challenges.

Market Trend: Increasing Adoption of Next-Generation Sequencing (NGS) Technology

A significant trend in the preimplantation genetic testing (PGT) market is the increasing adoption of next-generation sequencing (NGS) technology. NGS-based PGT methods offer higher resolution, throughput, and accuracy compared to traditional techniques, allowing for comprehensive screening of embryos for genetic abnormalities. With advancements in NGS platforms and bioinformatics tools, healthcare providers can offer more comprehensive PGT services, including aneuploidy screening, single-gene disorders detection, and chromosomal structural abnormalities assessment, leading to improved pregnancy outcomes and reduced risk of genetic disorders in offspring. This trend reflects a growing demand for advanced molecular diagnostic tools in assisted reproductive technology (ART) clinics and fertility centers to enhance the success rates of in vitro fertilization (IVF) procedures and ensure the birth of healthy babies.

Market Driver: Rising Demand for Assisted Reproductive Technologies (ART)

A key driver for the preimplantation genetic testing market is the rising demand for assisted reproductive technologies (ART) worldwide. Factors such as delayed childbearing, increasing infertility rates, and growing awareness of genetic disorders have led to a growing number of couples seeking fertility treatments to achieve pregnancy. Preimplantation genetic testing plays a critical role in ART procedures by identifying embryos with the highest likelihood of implantation and healthy development, thereby improving IVF success rates and reducing the risk of miscarriage and birth defects. As the demand for ART continues to rise, driven by changing demographics, lifestyle factors, and advancements in reproductive medicine, there is a corresponding increase in demand for preimplantation genetic testing services, driving market growth and innovation in the field of reproductive genetics.

Market Opportunity: Expansion of PGT Services for Preconception Screening

An emerging opportunity within the preimplantation genetic testing market lies in the expansion of PGT services for preconception screening. While PGT is traditionally performed during the IVF process to select embryos with desired genetic traits, there is a growing interest in offering PGT services for preconception screening to couples undergoing natural conception or other fertility treatments. Preconception PGT enables couples to assess their carrier status for genetic disorders, evaluate their risk of transmitting inherited conditions to their offspring, and make informed reproductive decisions based on their genetic profile. By expanding PGT services to include preconception screening, genetic counseling, and carrier testing, healthcare providers can empower individuals and couples to proactively manage their reproductive health, reduce the incidence of genetic diseases in future generations, and support informed family planning decisions, thereby unlocking new opportunities for growth and impact in the field of reproductive genetics.

Preimplantation Genetic Testing Market Share Analysis: Next-Generation Sequencing Technology Segment is the fastest growing segment over the forecast period to 2030

Within the preimplantation genetic testing market, the next-generation sequencing (NGS) technology segment is experiencing the fastest growth. This growth can be attributed to several factors. Firstly, NGS offers unparalleled capabilities for high-throughput, rapid, and comprehensive genetic analysis, allowing for the simultaneous screening of multiple genetic abnormalities with high sensitivity and accuracy. This is particularly advantageous for preimplantation genetic testing (PGT), where the detection of chromosomal abnormalities, single gene disorders, and other genetic variations is crucial for embryo selection and implantation. Secondly, advancements in NGS technology have led to improvements in sequencing accuracy, speed, and cost-effectiveness, making it increasingly accessible to fertility clinics, hospitals, and diagnostic laboratories performing PGT. Moreover, NGS-based PGT allows for the detection of a wide range of genetic abnormalities, including aneuploidy, structural chromosomal abnormalities, single gene disorders, and HLA typing, addressing the diverse needs of patients undergoing assisted reproductive procedures. As the demand for comprehensive and accurate genetic testing in assisted reproduction continues to rise, fueled by increasing awareness and advancements in fertility treatments, the NGS technology segment emerges as the fastest-growing segment within the preimplantation genetic testing market.

Preimplantation Genetic Testing Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, Agilent Technologies Inc, Illumina Inc, Oxford Nanopore Technologies Ltd, QIAGEN N.V., Revvity Health Inc, Takara Bio Inc, The Cooper Companies Inc, Thermo Fisher Scientific Inc, Vitrolife AB

Preimplantation Genetic Testing Market Segmentation

By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Preimplantation Genetic Testing Market Companies

Abbott Laboratories
Agilent Technologies Inc
Illumina Inc
Oxford Nanopore Technologies Ltd
QIAGEN N.V.
Revvity Health Inc
Takara Bio Inc
The Cooper Companies Inc
Thermo Fisher Scientific Inc
Vitrolife AB

Reasons to Buy the Preimplantation Genetic Testing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Preimplantation Genetic Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Preimplantation Genetic Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Preimplantation Genetic Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Preimplantation Genetic Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Preimplantation Genetic Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Preimplantation Genetic Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Preimplantation Genetic Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Preimplantation Genetic Testing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Preimplantation Genetic Testing Industry
4.2 Key Market Trends in Preimplantation Genetic Testing Industry
4.3 Potential Opportunities in Preimplantation Genetic Testing Industry
4.4 Key Challenges in Preimplantation Genetic Testing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Preimplantation Genetic Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Preimplantation Genetic Testing Market Outlook by Segments
7.1 Preimplantation Genetic Testing Market Outlook by Segments, $ Million, 2021- 2030
By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others

8 North America Preimplantation Genetic Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Preimplantation Genetic Testing Markets in 2024
8.2 North America Preimplantation Genetic Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Preimplantation Genetic Testing Market size Outlook by Segments, 2021-2030
By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others

9 Europe Preimplantation Genetic Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Preimplantation Genetic Testing Markets in 2024
9.2 Europe Preimplantation Genetic Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Preimplantation Genetic Testing Market Size Outlook by Segments, 2021-2030
By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others

10 Asia Pacific Preimplantation Genetic Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Preimplantation Genetic Testing Markets in 2024
10.2 Asia Pacific Preimplantation Genetic Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Preimplantation Genetic Testing Market size Outlook by Segments, 2021-2030
By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others

11 South America Preimplantation Genetic Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Preimplantation Genetic Testing Markets in 2024
11.2 South America Preimplantation Genetic Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Preimplantation Genetic Testing Market size Outlook by Segments, 2021-2030
By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others
12 Middle East and Africa Preimplantation Genetic Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Preimplantation Genetic Testing Markets in 2024
12.2 Middle East and Africa Preimplantation Genetic Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Preimplantation Genetic Testing Market size Outlook by Segments, 2021-2030
By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Agilent Technologies Inc
Illumina Inc
Oxford Nanopore Technologies Ltd
QIAGEN N.V.
Revvity Health Inc
Takara Bio Inc
The Cooper Companies Inc
Thermo Fisher Scientific Inc
Vitrolife AB

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Procedure
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Single-Nucleotide Polymorphism
By Product
Reagents and Consumables
Instruments
Software and Services
By Application
Aneuploidy
Structural Chromosomal Abnormalities
Single Gene Disorders
X-Linked Disorders
HLA Typing
Gender Identification
By Cycle
Fresh non-Donor
Frozen non-Donor
Fresh Donor
Frozen Donor
By End-User
Fertility Clinics
Hospitals
Diagnostic Laboratories
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)